Randomization

PA Paolo A. Ascierto
MC Milena Casula
JB Jenny Bulgarelli
MP Marina Pisano
CP Claudia Piccinini
LP Luisa Piccin
AC Antonio Cossu
MM Mario Mandalà
PF Pier Francesco Ferrucci
MG Massimo Guidoboni
PR Piotr Rutkowski
VF Virginia Ferraresi
AA Ana Arance
MG Michele Guida
EM Evaristo Maiello
HG Helen Gogas
ER Erika Richtig
MF Maria Teresa Fierro
CL Celeste Lebbe
HH Hildur Helgadottir
PQ Paola Queirolo
FS Francesco Spagnolo
MT Marco Tucci
MV Michele Del Vecchio
MC Maria Gonzales Cao
AM Alessandro Marco Minisini
SP Sabino De Placido
MS Miguel F. Sanmamed
DM Domenico Mallardo
MP Miriam Paone
MV Maria Grazia Vitale
IM Ignacio Melero
AG Antonio M. Grimaldi
DG Diana Giannarelli
RD Reinhard Dummer
VS Vanna Chiarion Sileni
GP Giuseppe Palmieri
request Request a Protocol
ask Ask a question
Favorite

Patients were randomized 1:1:1 across treatment arms. Arm A received encorafenib plus binimetinib until progressive disease [PD], followed by ipilimumab plus nivolumab until second PD. Arm B received ipilimumab plus nivolumab until PD followed by encorafenib plus binimetinib until second PD. Arm C (‘sandwich’ or ‘induction/maintenance’) received encorafenib plus binimetinib for 8 weeks followed by ipilimumab plus nivolumab until PD followed by encorafenib plus binimetinib until second PD). Patients were stratified by number of involved tumor sites and LDH elevation (IIIb/c – M1a – M1b, M1c with LDH ≤ 2ULN, and M1c with elevated LDH > 2 ULN).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A